Lin L.,Tianjin Medical University |
Lin L.,Tangshan Kailuan General Hospital |
Jin C.,Tangshan Kailuan General Hospital |
Wei X.,Tangshan Kailuan General Hospital |
And 5 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2015
Objective: The aim of this study is to examine and compare the efficacy of everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) in coronary heart disease in diabetic or non-diabetic patients. Methods: A total of 666 patients needed for percutaneous coronary intervention were randomly selected from June 2008 to June 2013 in our hospital and were divided into two groups: (i) coronary heart disease with diabetes group and (ii) nondiabetes group. Patients in each group were further assigned to receive treatment of either EES or ZES. Then we observed the major adverse cardiac events, including mortality, nonfatal myocardial infarction and non-fatal cerebrovascular events over the period of 15 months after initial stent implantation. Results: Compared to the non-diabetic group, more patients in diabetic group had received anti-hypotensive treatment (72% vs. 49%, P < 0.0001) and hypolipemic treatment (80% vs. 67%, P < 0.0001) before the percutaneous coronary intervention. In both diabetic group and non-diabetic group, patients received ZES treatment had a much greater incidence rate of major adverse cardiac events compared to the patients received EES treatment (P < 0.05). Meanwhile, target lesion revascularization rate in the ZES group was also significantly higher than that in the EES group. The data showed big differences between ZES and EES groups with important statistical significance (P < 0.05). Conclusion: Patients with coronary heart disease and diabetes have a higher risk of major adverse cardiac events after stent implantation. EES treatment is safer with higher efficacy in our study, being a more effective stent for the patients merged with diabetes. © 2015 E-Century Publishing Corporation. All rights reserved.
Yang X.,Tianjin Medical University |
Yang X.,Tangshan Maternal and Children Health Hospital |
Wang J.,Tianjin Medical University |
Wang J.,Tangshan Maternal and Children Health Hospital |
And 3 more authors.
European Journal of Gynaecological Oncology | Year: 2016
Purpose: To assess the complications and clinical outcomes of concurrent chemoradiotherapy (CCRT) or pure radiotherapy (RT) in local advanced cervical carcinoma (LACC) patients. Materials and Methods: A retrospective study was carried out in 113 consecutive LACC (FIGO Stage IB2-IIIB) patients, of whom 68 received CCRT; the others received pure RT. Five-year overall survival (OS) and the incidence, type, and severity of postoperative complications were analyzed. Results: The five-year survival rate for CCRT and pure RT were 67.7% and 46.8%, respectively (p = 0.018). The incidences of bone marrow suppression and gastrointestinal reaction for CCRT and pure RT were 100% vs. 88.89% (p < 0.001) and 70.6% vs. 33.33% (p < 0.001). Only 16.18% patients received CCRT developed chronic radiation enteritis, and 4.35% developed chronic radiation cystitis. While 11.11% patients received pure RT experienced chronic radiation enteritis (p = 0.449), 4.44% experienced chronic radiation cystitis (p = 0.312). Conclusions: This retrospective study demonstrated that CCRT followed by radical surgery achieved a better outcome compared with pure RT in LACC patients, but could apparently rise the incidence and severity of hematologic and gastrointestinal toxicity.